Can you take Wegovy with rheumatoid arthritis?

Jump to: What the evidence says | How obesity affects RA | RA medications and Wegovy | Foods to focus on | Staying active with RA | Looking after your mental health | When to speak to your GP | FAQs | Take home message

You can take Wegovy (semaglutide) if you have rheumatoid arthritis (RA).

RA isn’t listed as a reason to avoid Wegovy in the prescribing information, and there are no special warnings for people with autoimmune conditions.¹

Early evidence suggests GLP-1 receptor agonists (the class of medications that includes Wegovy, Mounjaro, and Ozempic) may improve RA outcomes.

A 2025 retrospective study found that RA disease activity and pain scores improved more in people taking a GLP-1 receptor agonist than in matched controls.²

Notably, these improvements were not closely correlated with weight loss, suggesting these drugs may have effects on inflammation and pain that go beyond their effect on appetite.

Obesity is associated with worse RA outcomes, lower remission rates, and reduced effectiveness of some biologic medications. Losing weight may improve all three.

This article focuses on RA specifically. Other forms of arthritis, such as osteoarthritis or psoriatic arthritis, have different considerations and aren’t covered here.

What the evidence says

GLP-1 receptor agonists and RA disease activity

A 2025 study by Kellner and colleagues in ACR Open Rheumatology examined 173 RA patients with a BMI of 27 or higher who were prescribed a GLP-1 receptor agonist (semaglutide or tirzepatide), compared with 42 controls.²

After 12 months, the treatment group had significantly greater reductions in RA disease activity, pain scores, and several markers of cardiovascular risk, including total cholesterol and HbA1c (a measure of average blood sugar levels).²

Importantly, neither pain reduction nor reductions in inflammatory markers (ESR, CRP) were significantly correlated with weight loss in this study.²

The authors suggest the medications may affect inflammation and pain through mechanisms other than appetite reduction, though this needs confirmation in prospective trials.

Still, this study had its limitations. It was a single-centre retrospective chart review; the treatment and control groups had different baseline characteristics, RA disease activity was assessed from clinic notes rather than from validated DAS28 or CDAI scores, and 29% of the treatment group stopped taking their GLP-1 medication during the study period.

Anti-inflammatory effects on lab markers

A 2025 meta-analysis of 52 randomised controlled trials in patients with type 2 diabetes (not RA) found that GLP-1 receptor agonists significantly reduced circulating levels of inflammatory compounds CRP, TNF-alpha, IL-6, and IL-1beta.⁹

These are inflammatory markers that also contribute to RA. Whether reducing them in the blood actually slows joint damage in people with RA hasn’t yet been tested directly.

Weight loss and RA outcomes

A 2023 randomised controlled trial by Ranganath and colleagues assigned 40 RA patients with obesity to either a low-calorie diet intervention (1000-1500 kcal/day with meal replacements) or usual care for 12 weeks.⁴

The diet group lost an average of 9.5 kg, compared to 0.5 kg in controls.

DAS28 disease activity scores improved within the diet group from 5.2 to 4.2, though the difference between groups was not statistically significant.

Other measures improved significantly more in the diet group than in controls, including a self-reported disease activity questionnaire and blood markers linked to fat tissue inflammation.⁴

A separate meta-analysis found that obesity at RA diagnosis reduces the likelihood of achieving remission by 43% and sustained remission by 51%.³

How obesity affects RA

Around 1% of adults in the UK have RA, and obesity is increasingly common among people with the condition. The two interact in several ways that affect treatment.

Fat tissue produces inflammatory molecules, including TNF-alpha and IL-6.

These are the same molecules that drive RA inflammation, so carrying excess weight adds to the inflammatory load on your joints.

Obesity also affects how well RA treatments work.

A study of over 10,000 RA patients found that obesity reduces the effectiveness of TNF inhibitors such as adalimumab and etanercept, whereas cell-targeted therapies such as rituximab appear unaffected by body weight.¹⁰

This finding has a practical implication that’s not widely discussed: if a TNF inhibitor stopped working as well as it used to, weight loss may help restore some of its effectiveness rather than requiring a switch to a different biologic.

Mechanically, excess weight places additional strain on weight-bearing joints, such as the knees and hips, which can worsen pain even when disease activity is well controlled.

RA medications and Wegovy

There are no published drug interactions between semaglutide and common RA medications.

The Wegovy SmPC notes that at the maintenance dose, no clinically relevant effect on gastric emptying was observed.¹

Your RA medications can continue as prescribed:

• Oral DMARDs (methotrexate, sulfasalazine, hydroxychloroquine, leflunomide) are unlikely to be affected, as semaglutide doesn’t meaningfully change how much of these drugs your body absorbs
• Biologic DMARDs (adalimumab, etanercept, tocilizumab, rituximab) are given by injection or infusion, so they bypass the gut entirely
• JAK inhibitors (tofacitinib, baricitinib) are oral medications with no published interaction data, but the same reassurance applies

Methotrexate

Methotrexate is the cornerstone of RA treatment for most people.

Methotrexate requires adequate hydration to be cleared by the kidneys.

Wegovy’s gastrointestinal side effects can cause dehydration, particularly during dose escalation, which could affect methotrexate clearance.

Drink enough fluid daily and tell your rheumatology team if you’re struggling to keep fluids down.

Methotrexate can cause mucositis (mouth ulcers and gut lining inflammation), and Wegovy can cause nausea and reduced appetite. Together, this can make eating uncomfortable or difficult.

Folic acid supplementation (which most people on methotrexate already take) helps reduce the risk of mucositis.

Alcohol can interact with methotrexate to increase the risk of liver problems.

NHS guidance is to limit alcohol to 14 units per week if you’re on methotrexate, with some rheumatologists recommending less.

Corticosteroids

If you take prednisolone or another corticosteroid, weight loss from Wegovy may allow your dose to be reduced over time.

Long-term low-dose corticosteroids are common in RA, and any opportunity to reduce them is generally welcomed by both patients and rheumatologists because of the long-term side effects (bone density loss, blood sugar effects, infection risk).

Don’t reduce your steroid dose without medical supervision, as sudden withdrawal can cause adrenal insufficiency.

NSAIDs

If you’re taking NSAIDs (ibuprofen, naproxen, diclofenac) for RA pain relief, both NSAIDs and Wegovy can cause gastrointestinal side effects.

Taking NSAIDs with food and discussing gastroprotection with your GP is sensible.

NSAIDs can also affect kidney function, and dehydration from Wegovy’s GI side effects compounds this risk.

Stay well hydrated and contact your GP if you notice reduced urine output, swelling, or unexplained fatigue.

You can read more in our guide on painkillers while on Wegovy.

Missing doses during side effects

If GI side effects from Wegovy mean you’re vomiting or unable to tolerate oral medications, contact your rheumatology team rather than just stopping.

Missing doses of methotrexate or other DMARDs can trigger an RA flare.

Your team may suggest temporary switches (such as injectable methotrexate) or a brief dose adjustment until side effects settle.

Foods to focus on

A diet based on whole foods, with adequate protein, oily fish, vegetables, and extra-virgin olive oil, is associated with better RA outcomes in observational studies.

The 2020 Schönenberger systematic review found moderate-strength evidence for Mediterranean-style eating patterns reducing RA disease activity, though the evidence base is smaller than for diabetes or cardiovascular disease.

Anti-inflammatory foods

• Oily fish (salmon, mackerel, sardines) for omega-3 fatty acids, which have been shown to reduce tender joint count and morning stiffness in RA
• Colourful vegetables and fruits for antioxidants: leafy greens, berries, peppers, tomatoes
• Extra virgin olive oil as a primary cooking fat
• Nuts and seeds (walnuts, flaxseeds, chia seeds) for additional omega-3s

Protein for maintaining muscle mass

Both RA itself and corticosteroid use can contribute to muscle wasting; adequate protein intake can help protect muscle in this scenario.

Aim for a palm-sized portion of protein at each meal to help preserve muscle during weight loss.

• Lean protein sources: chicken, turkey, fish, eggs, lentils, tofu
• Dairy or fortified alternatives for calcium, particularly important if you take corticosteroids that can affect bone density

Complex carbohydrates and fibre

• Wholegrain or sourdough bread, oats, brown rice, sweet potato, quinoa
• Beans and lentils, which provide both fibre and plant-based protein
• A high-fibre diet supports gut health, which is increasingly linked to autoimmune disease management

Foods to limit

• Ultra-processed foods, which tend to promote inflammation
• Sugary drinks and refined carbohydrates
• Excess alcohol, which can interact with RA medications (particularly methotrexate)

Bone health

RA, corticosteroids, and rapid weight loss can all affect bone density.

Adequate calcium (700 mg per day for adults) and vitamin D (10 micrograms per day, particularly in winter) are important.

Many people on long-term steroids are also prescribed bisphosphonates to protect bone density.

If you’re losing weight quickly on Wegovy, bone-loading exercise and adequate protein become particularly relevant.

Staying active with RA

Regular physical activity is one of the non-medication treatments for RA with a strong evidence base.

It reduces pain, improves function, and helps preserve muscle mass and bone density.

NICE recommends that people with RA have access to specialist physiotherapy, so ask your GP for a referral if you haven’t already.⁵

Getting started

Research on habit formation suggests that linking a new behaviour to an existing routine helps it become automatic over time.⁶ A 10-minute walk after a meal is a practical starting point.

If joint pain makes walking difficult, low-impact options like swimming, cycling, or aquatic exercise put less stress on joints while still providing cardiovascular benefit.

Gradually doing a little more as it feels manageable is the right approach. You might extend a walk by five minutes, add a second short session during the day, or try a different activity.

Resistance training for joint protection

Strengthening the muscles around affected joints helps support and protect them.

Resistance training is safe for most people with RA and is recommended by both NICE and the British Society for Rheumatology.

Start with bodyweight exercises like wall push-ups, seated leg raises, or resistance band work.

You could try ‘exercise snacking’: a few squats while waiting for the kettle to boil, or calf raises during a phone call.

Begin at a low intensity and build gradually. Training on alternate days gives your joints time to recover between sessions.

During a flare

During an RA flare, it’s recommended to reduce intensity while trying to keep moving.

Gentle stretching and range-of-motion exercises can help maintain joint flexibility without aggravating inflammation.

Short, frequent sessions (three 10-minute walks rather than one 30-minute walk) are often more manageable during a flare. Avoid strengthening exercises until the flare settles.

Looking after your mental health

Depression is roughly twice as common in people with RA as in the general population, and anxiety is also significantly more prevalent.

Several factors contribute to this. Chronic pain and fatigue affect your ability to do everyday tasks.

Flares are unpredictable, making it hard to plan ahead. RA medications can have side effects that affect mood and energy. And visible changes to joints can affect body image and self-confidence.

Wegovy adds another set of things to track on top of RA: injection schedules, dietary adjustments, potential side effects, and monitoring appointments.

NICE recommends that annual RA reviews include an assessment of mood and wellbeing.⁵

If you’re struggling, raise it with your GP or rheumatology team.

Many specialist rheumatology services have psychologists attached and can refer you internally.

Versus Arthritis and the National Rheumatoid Arthritis Society (NRAS) both offer emotional support and practical guidance for people living with RA.

When to speak to your GP

Contact your GP or rheumatologist if you experience:

• A significant RA flare after starting Wegovy or changing dose
• Persistent nausea or vomiting that affects your ability to take oral RA medications consistently
• New or worsening joint symptoms that don’t follow your usual flare pattern
• Dehydration symptoms (dark urine, reduced urine output, dizziness), particularly if you take methotrexate, which requires adequate hydration for kidney clearance
• Significant weight loss that might affect your RA medication dosing
• Stomach pain or GI symptoms that are worse than expected, especially if you’re taking NSAIDs or corticosteroids alongside Wegovy
• Feelings of low mood, anxiety, or being overwhelmed by managing your condition

Frequently asked questions

Is Wegovy safe with rheumatoid arthritis?

Yes. RA isn’t listed as a contraindication or special warning in the Wegovy prescribing information.¹

Early research suggests GLP-1 receptor agonists may also improve RA disease activity and pain, though larger prospective trials are needed to confirm this.²

Will Wegovy interact with my RA medications?

No published interactions exist between semaglutide and common RA medications, including methotrexate, sulfasalazine, hydroxychloroquine, biologics, or JAK inhibitors.¹

Biologic DMARDs are given by injection, so they bypass the gut entirely.

Can weight loss improve my RA?

Probably yes. Obesity is associated with reduced odds of RA remission and lower response rates to some biologic medications.^3,10

A 12-week weight-loss trial in people with RA and obesity showed improvements in disease activity in the diet group, though the between-group difference didn’t reach statistical significance.⁴

Will Wegovy reduce my joint inflammation?

The honest answer is we don’t yet know. Semaglutide reduces circulating inflammatory markers like CRP, TNF-alpha, and IL-6 in studies of people with type 2 diabetes.⁹

Whether this translates to a noticeable difference in joint pain in RA isn’t clear. Wegovy isn’t an RA treatment and shouldn’t replace your RA medications.

Should I tell my rheumatologist I’m starting Wegovy?

Yes. Your rheumatologist needs to know about all your medications.

As you lose weight, your RA medication doses may need adjusting, your steroid dose may be able to come down, and your disease activity should be monitored.

Can I exercise with RA while on Wegovy?

Yes. NICE recommends regular exercise for people with RA, including both aerobic activity and resistance training.⁵ Start small and build gradually.

During flares, reduce intensity but try to keep moving with gentle stretching.

What should I eat to help both RA and weight loss?

A diet based on whole foods, including oily fish, vegetables, olive oil, nuts, and wholegrains, has the strongest observational evidence for RA. This aligns with balanced eating for weight management on Wegovy.

Will my biologic still work if I lose weight?

Some biologics, particularly TNF inhibitors such as adalimumab, are less effective in higher body weights.¹⁰

Losing weight may improve how well your biologic works. If a TNF inhibitor previously worked well but has stopped, this is worth discussing with your rheumatologist before assuming you need to switch.

Does Wegovy affect the immune system?

Semaglutide isn’t an immunosuppressant. It doesn’t suppress the immune system in the way that RA medications like methotrexate or biologics do, so it’s safe to use alongside immunosuppressive RA treatments.

Can I get Wegovy on the NHS if I have RA?

NICE recommends semaglutide for weight management in eligible adults under TA875, which requires referral to a Tier 3 specialist weight management service.

Having RA doesn’t disqualify you, but the specialist service should coordinate with your rheumatology team.

Take home message

Wegovy can be taken safely alongside RA, with no published drug interactions with common RA medications.

Early research suggests GLP-1 receptor agonists may improve RA disease activity, pain, and inflammatory markers, with some evidence that these effects may go beyond what weight loss alone would explain.² Larger prospective trials are needed to confirm this.

Obesity is associated with worse RA outcomes and reduced effectiveness of some biologic medications.^3,10

Weight loss may meaningfully improve disease activity and treatment response.

A diet based on whole foods, rich in oily fish, vegetables, olive oil, and wholegrains supports both RA management and weight loss on Wegovy.

Regular exercise helps protect joints and maintain muscle mass.

Second Nature’s programme combines medication support with personalised nutrition guidance from registered dietitians and nutritionists, built around a balanced plate of vegetables, protein, complex carbohydrates, and healthy fats.

A peer-reviewed study published in JMIR Formative Research found that active subscribers on Second Nature’s semaglutide-supported programme lost an average of 19.1% of their body weight at 12 months, with 77.7% achieving at least 10% weight loss.⁷

References

1. Electronic Medicines Compendium. (2026). Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen: Summary of Product Characteristics.
2. Kellner, D.A. et al. (2025). Effect of glucagon-like peptide 1 receptor agonists on patients with rheumatoid arthritis. ACR Open Rheumatology, 7(9), e70103.
3. Liu, Y. et al. (2017). Impact of obesity on remission and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care & Research, 69(2), 157-165.
4. Ranganath, V.K. et al. (2023). Improved outcomes in rheumatoid arthritis with obesity after a weight loss intervention: randomized trial. Rheumatology (Oxford), 62(2), 565-574.
5. NICE. (2018). Rheumatoid arthritis in adults: management. NG100.
6. Lally, P. et al. (2010). How are habits formed: modelling habit formation in the real world. European Journal of Social Psychology, 40(6), 998-1009.
7. Richards, R. et al. (2025). A remotely delivered GLP-1RA-supported specialist weight management program in adults living with obesity: retrospective service evaluation. JMIR Formative Research, 9, e72577.
8. Schönenberger, K.A. et al. (2021). Effect of anti-inflammatory diets on pain in rheumatoid arthritis: a systematic review and meta-analysis. Nutrients, 13(12), 4221.
9. Ren, Y. et al. (2025). The effect of GLP-1 receptor agonists on circulating inflammatory markers in type 2 diabetes patients: a systematic review and meta-analysis. Diabetes, Obesity and Metabolism.
10. Schafer, M. et al. (2020). Obesity reduces the real-world effectiveness of cytokine-targeted but not cell-targeted disease-modifying agents in rheumatoid arthritis. Rheumatology, 59(8), 1916-1926.